Value
6.3/10data confidence 33%| Component | Sub-score |
|---|---|
| P/S | 2.2 |
| Analyst target | 9.0 |
MOBI · Why this verdict
Why Mobia Medical (MOBI) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score5.9/10
ConfidenceMEDIUM
MacroNEUTRAL
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
The company's most recent quarter missed EPS estimates by a very wide margin, raising doubts about near-term execution. Earnings | The company should deliver at least an inline or beat quarter in its next report. | →Stable |
| CounterA large analyst-implied upside suggests the market may be looking past a single miss toward the underlying growth story. | ||
Revenue is growing at an exceptional 113% year over year, signaling strong demand for the company's medical device offerings. Growth breakdown | Revenue growth should stay above 30% YoY over the next 12 months. | →Stable |
| CounterHigh growth off a small base can decelerate sharply, and the company's recent large earnings miss suggests execution risk behind the top-line number. | ||
Price momentum has broken down, with the engine's momentum score sitting below its required threshold and volume showing distribution rather than accumulation. Warnings | The momentum score should recover above the engine's 4.5 threshold over the next 2 quarters. | →Stable |
| CounterThe company's exceptionally strong revenue growth could reassert upward price momentum once earnings stabilize. | ||
An insider recently bought stock, a modestly bullish signal that management sees value at current levels. Insider | Insider buying activity should continue or increase in scale over the next quarter. | →Stable |
| CounterThe buy amount is small relative to market capitalization, limiting how strong a signal this really is. | ||
The company's most recent quarter missed EPS estimates by a very wide margin, raising doubts about near-term execution.
→StableEarnings
- Expectation
- The company should deliver at least an inline or beat quarter in its next report.
CounterA large analyst-implied upside suggests the market may be looking past a single miss toward the underlying growth story.
Revenue is growing at an exceptional 113% year over year, signaling strong demand for the company's medical device offerings.
→StableGrowth breakdown
- Expectation
- Revenue growth should stay above 30% YoY over the next 12 months.
CounterHigh growth off a small base can decelerate sharply, and the company's recent large earnings miss suggests execution risk behind the top-line number.
Price momentum has broken down, with the engine's momentum score sitting below its required threshold and volume showing distribution rather than accumulation.
→StableWarnings
- Expectation
- The momentum score should recover above the engine's 4.5 threshold over the next 2 quarters.
CounterThe company's exceptionally strong revenue growth could reassert upward price momentum once earnings stabilize.
An insider recently bought stock, a modestly bullish signal that management sees value at current levels.
→StableInsider
- Expectation
- Insider buying activity should continue or increase in scale over the next quarter.
CounterThe buy amount is small relative to market capitalization, limiting how strong a signal this really is.
TrendMatrix Research · core thesis
Engine thesis — one sentence
Mobia Medical shows explosive 113% revenue growth and a bullish insider buy, but a failed momentum gate and a severe recent earnings miss keep the near-term setup risky and unproven.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Per-dimension breakdown
Quality
7.2/10data confidence 57%| Component | Sub-score |
|---|---|
| Gross margin | 10.0 |
| Current ratio | 6.9 |
| Moat | 6.5 |
| Piotroski F | 5.6 |
Growth
10.0/10data confidence 33%| Component | Sub-score |
|---|---|
| Rev growth | 10.0 |
- ▸Strong growth: 113% YoY
Momentum
3.2/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 4.5 |
| MACD | 3.5 |
| OBV | 1.0 |
| MA position | 6.5 |
| Volume | 0.5 |
- ▸Volume distribution (falling OBV)
Sentiment
7.2/10data confidence 100%| Component | Sub-score |
|---|---|
| LLM sentiment | 7.5 |
| Analyst rating | 5.0 |
| Price target | 9.6 |
- ▸LLM news sentiment: +0.50 (n=1)
- ▸Analyst upside: 51%
Insider
5.5/10data confidence 25%| Component | Sub-score |
|---|---|
| materiality | 5.5 |
- ▸Insider buying (low materiality) — $63,969 (0.014% of mkt cap)
Peer rank
2.7/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 1.0 |
| quality rank | 0.0 |
| growth rank | 9.7 |
- ▸Industry growth leader
Technical
5.6/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 4.9 |
| support resistance | 4.5 |
| 52w position | 7.3 |
Risk (lower is worse)
3.6/10data confidence 80%| Component | Sub-score |
|---|---|
| short interest | 7.9 |
| days to cover | 5.7 |
| volatility | 0.0 |
| debt equity | 0.9 |
Catalyst
1.7/10data confidence 75%| Component | Sub-score |
|---|---|
| earnings history | 0.0 |
| surprise avg | 0.0 |
| news activity | 5.0 |
How the verdict was assembled
Engine trigger
Multiple concerning factors. Consider reducing position.
Engine technical detail
verdict_path:
L4:PATH_F_SELLPassed (6)
- ASYMMETRY:2.1>=1.5
- INSIDER:OK
- 8K:CLEAN
- EARNINGS_PROXIMITY:NO_DATE
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- MOMENTUM:3.2<4.5
Warning (0)
none
Reward-to-Risk
2.09
Upside
+31.3%
Downside
15.0%
Sizing output
AVOID
SetupRange Bound — RSI 55 mid-range, Bollinger mid-band
EdgeNo clear edge — No clear edge identified
SuitabilityAggressive — MCap $0.5B<$5B
Investment implication
The F-path SELL output reflects an overall score of 4.4 below the 5.6 soft trigger — multiple weakening dimensions accumulated rather than a single hard-floor breach. The strongest dimension ( Growth at 10.0) was not enough to lift the adjusted overall above the threshold. Co-occurring failed gates ( MOMENTUM:3.2<4.5) reinforce the read. Current asymmetry R:R is 2.09 — supplementary context, not the trigger for this path.
The strongest dimensions are Growth at 10.0, Quality at 7.2, and Sentiment at 7.2; the weakest are Catalyst at 1.7, Peer rank at 2.7, and Momentum at 3.2. The V9 engine flagged 1 failed gate, producing an asymmetric reward-to-risk of 2.09 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Revenue Growth Acceleration
Trip ifRevenue growth falls below 30% YoY for 2 consecutive quarters, down from the current 113% YoY pace.
- P2Momentum Gate Failure
Trip ifMomentum score stays below 4.5 for 3 consecutive quarters.
- P3Insider Buying Signal
Trip ifNet insider transactions turn to net selling that exceeds $100,000 within 90 days.
- P4Earnings Miss Execution Risk
Trip ifEPS surprise exceeds +10% (a clean beat) in the next reported quarter.